К. Карчер
Johnson & Johnson (United States) · 14 works · 95 citations · h-index 6
Top works
- Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
- Acute postoperative pain relief with immediate-release tapentadol: randomized, double-blind, placebo-controlled study conducted in South Korea
- Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour‐related pain
- Efficacy, safety, and tolerability of fulranumab in treatment of patients with moderate-to-severe, chronic low back pain
- Efficacy and tolerability of tapentadol extended release (ER) in patients with chronic, painful diabetic peripheral neuropathy (DPN): results of a phase 3, randomized-withdrawal, placebo-controlled study
- Efficacy and safety of a novel long-acting risperidone formulation
- Long-acting injectable risperidone: Efficacy and safety
- Long-acting risperidone microspheres for treatment of patients with schizophrenia
- POS1130 DESIGNING OF A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCRN INHIBITOR, IN ADULTS WITH PRIMARY SJÖGREN'S SYNDROME
- Effect of esketamine nasal spray on cognition in patients with treatment-resistant depression: results from five phase-3 studies
- Лечение шизофрении пролонгированным инъекционным рисперидоном: открытое 12-месячное исследование первого пролонгированного антипсихотика второго поколения
- 73PLong-term safety and efficacy of nipocalimab in generalized myasthenia gravis: vivacity-MG3 open-label extension phase results
- P.2.087 Risperidone monotherapy in acute bipolar mania
- P.038 Effect of esketamine nasal spray on cognition in patients with treatment-resistant depression: results from five phase-3 studies